Dimerix (ASX:DXB) Successfully Completes IDMC Review for ACTION3 Phase 3 Trial
Dimerix (ASX:DXB) successfully completes IDMC review of ACTION3 Phase 3 trial, affirming DMX-200’s safety profile.
Category: ASX-DXB
Dimerix Limited
Dimerix Limited (ASX:DXB) Secures Major Licensing Deal in Japan and FDA Endorsement for DMX-200
Dimerix Limited (ASX:DXB) secures a ¥10.5 billion licensing deal in Japan and receives FDA endorsement for its DMX-200 therapy.